

The SPironolactone and ACEtazolamide (SPACE) trial in the prevention of acute mountain sickness

Submission date 30/07/2007	Recruitment status No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
Registration date 04/09/2007	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
Last Edited 24/11/2008	Condition category Signs and Symptoms	<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Buddha Basnyat

Contact details

Nepal International Clinic

Lal Durbar

GPO BOX 3596

Kathmandu

Nepal

1

rishibas@wlink.com.np

Additional identifiers

Protocol serial number

OXTREC 1

Study information

Scientific Title

Acronym

SPACE

Study objectives

Acute Mountain Sickness (AMS) is like a hangover (headache, nausea and tiredness being prominent features) that may manifest at altitudes greater than 2600 m when people ascend too high too fast.

This is a study to ascertain the benefit of spironolactone (aldactone), a water pill, in the prevention of AMS which comprises of headache, nausea and tiredness at altitude greater than 2700 m. Acetazolamide (Diamox®) which we know works for the prevention of AMS will be compared with spironolactone and a placebo or a sugar pill.

Hypothesis:

Spironolactone will prevent AMS.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Added 24/11/2008: OXTREC approval on 07/10/2008 for the study (031 07).

Study design

Randomised, double blind, placebo controlled trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Acute mountain sickness

Interventions

This is a prospective three armed, double blind, randomised, placebo controlled trial. Computer generated randomisation of spironolactone, acetazolamide and placebo will be carried out. After consent is obtained, participants will receive a four days supply of either spironolactone 50 mg twice daily (bid), acetazolamide 250 mg bid or visually matched placebo bid. Trekkers will be enrolled in the study and baseline measurements done at Pheriche (4300 m) and reassessed after their arrival at the endpoint in Lobuje (5000 m). The reassessment will take place at least 36 hours to a maximum of 96 hours (4 days) after taking the study drug.

Assessments and measurements will be made in these areas prior to and after ascension on the study drug:

1. Lake Louise Questionnaire
2. Oxygen saturation via pulse oximetry

The approach to Everest Base Camp provides a unique study population for the following reasons:

1. Large numbers of recently arrived (non-acclimated) trekkers

2. Relatively homogenous population (gender, age, physical fitness, etc.) with relatively few pre-existing conditions
3. Linear population movement along the approach
4. Rapid and quantitatively large elevation change (about 700 m)

Data will also be collected on the demographics of the study population at the enrolment site. The study will not provide financial assistance in the event of the development of complications of being at high altitude.

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Spironolactone, acetazolamide

Primary outcome(s)

Main outcome measure will be incidence of AMS measured by Lake Louise acute mountain sickness score (LLscore) greater than or equal to three with headache and at least one other symptom.

Outcomes will be measured at baseline (Pheriche 4300 m) and remeasured at Lobuje (5000 m). The reassessment will take place at least 36 hours to a maximum of 96 hours (four days) after taking the study drug.

Key secondary outcome(s)

1. Oxygen saturation measured by pulse oximeter
2. Severity of symptom (LLscore greater than five)
3. Incidence of headache and severity of headache

Outcomes will be measured at baseline (Pheriche 4300 m) and remeasured at Lobuje (5000 m). The reassessment will take place at least 36 hours to a maximum of 96 hours (four days) after taking the study drug.

Completion date

25/11/2007

Eligibility

Key inclusion criteria

1. Healthy subjects between the ages of 18 and 65
2. Male or female
3. Non-Nepali
4. Without AMS or any concurrent illness
5. Not already taking acetazolamide or any other drug for the prevention of altitude illness

Subjects will be enrolled by study administrators en route directly to Everest Base Camp or Kala Patthar between the villages of Pheriche/Dingboche and Lobuje.

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

Not Specified

Key exclusion criteria

1. Individuals not meeting inclusion criteria, including mild AMS (more than one mild symptom on the Lake Louise Questionnaire) or significantly depressed oxygen saturation (less than 75%)
2. Females known to be pregnant, or cannot exclude the possibility of being pregnant, or have missed menses by over seven days
3. Individuals with a known drug allergy to acetazolamide or other sulfa drugs
4. Individuals who are on Angiotensin-Converting Enzyme (ACE) inhibitors (like enalapril) or other diuretics like amiloride or triamterene, as concurrent administration with spironolactone can cause hyperkalemia
5. Individuals who have spent 24 hours at an altitude of 4500 metres/14,000 feet within the last nine days
6. Anyone known to have taken any of the following in the last two days:
 - 6.1. Acetazolamide (Diamox®)
 - 6.2. Steroids (dexamethasone, prednisone)
 - 6.3. Theophylline
 - 6.4. Diuretics (Lasix®)
7. Individuals who have a known intracranial space occupying lesion or a history of elevated intracranial pressure, (i.e. tumours, hydrocephalus, etc)
8. Lack of informed consent will obviously mandate exclusion

Date of first enrolment

10/10/2007

Date of final enrolment

25/11/2007

Locations**Countries of recruitment**

Nepal

Study participating centre

Nepal International Clinic

Kathmandu

Nepal
1

Sponsor information

Organisation

University of Oxford (UK)

ROR

<https://ror.org/052gg0110>

Funder(s)

Funder type

Research organisation

Funder Name

Oxford University Clinical Research Unit (Vietnam) (ref: HB0075)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration